
Opinion|Videos|September 27, 2024
Treatment Landscape for Transplant-Eligible Patients with NDMM
Panelists discuss how the current first-line treatment options for transplant-eligible patients with newly diagnosed multiple myeloma (NDMM) typically involve combination therapies including proteasome inhibitors, immunomodulatory drugs, and steroids.
Advertisement
Episodes in this series

Now Playing
Video content above is prompted by the following:
- Provide a brief overview of first-line treatment options currently available for transplant-eligible patients with newly diagnosed multiple myeloma (NDMM).
Newsletter
Stay informed on drug updates, treatment guidelines, and pharmacy practice trends—subscribe to Pharmacy Times for weekly clinical insights.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Pharmacy Times
1
Advancing Treatment After CDK4/6 Inhibitor Progression in HR+/HER2– Breast Cancer
2
Pharmacists, Don’t Fear AI: ASHP Framework Shows How to Embrace AI
3
A Supplemental Blood Test to Bridge Gaps in Breast Cancer Screening Access
4
How IV Robotics Are Transforming Sterile Compounding, Supply Chain Control, and Workforce Efficiency
5




















































































































































































































